Top 10 Companies in the (R)-(-)-1-Methyl-3-hydroxypyrrolidine (CAS No. 104641-60-3) Market (2026): Market Leaders Driving Global Pharmaceutical Synthesis

MARKET INSIGHTS

Global (R)-(-)-1-Methyl-3-hydroxypyrrolidine (CAS No. 104641-60-3) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.4% during the forecast period.

(R)-(-)-1-Methyl-3-hydroxypyrrolidine (CAS No. 104641-60-3) is a chiral pyrrolidine derivative characterized by its (R)-configuration at the 3-position, featuring a hydroxyl functional group and an N-methyl substituent on the pyrrolidine ring. This optically active compound serves as a valuable chiral building block and synthetic intermediate in pharmaceutical development, particularly in the synthesis of enantiomerically pure active pharmaceutical ingredients (APIs) and fine chemicals.

The market is witnessing steady growth driven by rising demand for chiral intermediates in drug discovery and the increasing emphasis on stereoselective synthesis across the pharmaceutical industry. Furthermore, expanding research activities in asymmetric synthesis and the growing pipeline of small-molecule therapeutics requiring pyrrolidine-based scaffolds are reinforcing market momentum. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Combi‑Blocks, among other specialty fine chemical manufacturers.

(R)-(-)-1-Methyl-3-hydroxypyrrolidine (CAS No. 104641-60-3) Market – View in Detailed Research Report

Top 10 Companies in the (R)-(-)-1-Methyl-3-hydroxypyrrolidine Market (2026)

1️⃣ Hairui Fine Chemicals Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Pharmaceutical‑grade (R)-(-)-1‑Methyl‑3‑hydroxypyrrolidine

Hairui Fine Chemicals has established a reputation for delivering high‑purity chiral intermediates to major pharma clients. Their state‑of‑the‑art asymmetric hydrogenation platform enables rapid scale‑up, meeting the stringent purity requirements of contemporary drug candidates.

Sustainability Initiatives: Investment in green hydrogen‑based processes and waste‑reduction protocols.

• Dedicated R&D budget for chiral catalyst development
• ISO 9001 and GMP certification across all production lines
• Partnerships with leading CNS drug developers

2️⃣ Capot Chemical Co., Ltd.

Headquarters: Beijing, China
Key Offering: Research‑grade chiral intermediates for academic and industrial use

Capot Chemical focuses on providing customizable synthesis routes, allowing clients to tailor stereochemical purity and functional group placement to specific API designs.

Sustainability Initiatives: Implementation of continuous flow reactors to reduce solvent usage.

• ISO 14001 environmental management system
• Collaborations with universities for process innovation
• Export‑ready production capacity exceeding 200 kg/month

3️⃣ Finetech Industry Limited

Headquarters: Shenzhen, China
Key Offering: Industrial‑grade chiral building blocks for large‑scale API production

Finetech leverages high‑throughput catalytic platforms to deliver cost‑effective solutions for generic manufacturers, maintaining consistent enantiomeric excess across batches.

Sustainability Initiatives: Focus on low‑energy consumption and recyclable solvents.

• Continuous flow synthesis capabilities
• Partnerships with contract manufacturers
• Robust quality control laboratories

4️⃣ Hairui Chemical

Headquarters: Shanghai, China
Key Offering: Custom synthesis and purification services for niche research projects

Hairui Chemical offers end‑to‑end solutions, from raw material sourcing to final purification, ensuring compliance with the highest regulatory standards.

Sustainability Initiatives: Development of biocatalytic resolution methods.

• GMP‑certified production lines
• Active participation in industry consortia for chiral synthesis standards
• Rapid turnaround times for pilot‑scale orders

5️⃣ Shanghai Trustin Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: High‑purity chiral intermediates for specialty pharmaceuticals

Trustin’s integrated facilities enable seamless scale‑up from laboratory to commercial production, catering to emerging markets in oncology and neurology.

Sustainability Initiatives: Adoption of renewable energy sources for manufacturing.

• ISO 9001 and GMP certifications
• Strategic alliances with European pharma companies
• Advanced chromatographic purification technologies

6️⃣ Enamine Ltd.

Headquarters: Kyiv, Ukraine
Key Offering: Diverse catalog of fine chemicals including chiral intermediates

Enamine’s global reach and flexible production model make it a preferred partner for both academic and industrial clients seeking tailored synthesis routes.

Sustainability Initiatives: Focus on green chemistry and waste minimization.

• ISO 14001 certification
• Collaborations with European research institutes
• High‑throughput synthesis platforms

7️⃣ Clearsynth

Headquarters: Bangalore, India
Key Offering: Custom chiral synthesis and resolution services

Clearsynth’s expertise in enzymatic resolution positions it as a key player in the Indian market, providing cost‑effective solutions for local API developers.

Sustainability Initiatives: Promotion of enzyme‑based processes to reduce chemical waste.

• ISO 9001 and GMP compliance
• Strong presence in the Indian generics sector
• Rapid scale‑up capabilities for pilot projects

8️⃣ Biosynth Carbosynth

Headquarters: Basel, Switzerland
Key Offering: High‑purity chiral intermediates for biopharmaceuticals

Biosynth Carbosynth combines Swiss precision chemistry with robust supply chains, delivering products that meet the stringent demands of biologics and peptide therapeutics.

Sustainability Initiatives: Investment in renewable energy and carbon‑neutral production processes.

• ISO 9001, ISO 14001, and GMP certifications
• Partnerships with leading biotech firms
• Advanced process analytical technology (PAT) implementation

9️⃣ Hunan Aslsen Biotechnology Co., Ltd.

Headquarters: Changsha, China
Key Offering: Research‑grade chiral intermediates for academic and small‑scale industrial use

Hunan Aslsen focuses on rapid prototyping and small‑batch production, enabling early‑stage drug discovery projects to access high‑quality chiral building blocks.

Sustainability Initiatives: Development of low‑solvent, high‑yield synthetic routes.

• ISO 9001 certification
• Active collaboration with Chinese universities
• Flexible contract manufacturing services

🔟 Senova Technology Co., Ltd.

Headquarters: Wuhan, China
Key Offering: Industrial‑grade chiral intermediates for large‑scale API manufacturing

Senova’s production lines are optimized for high throughput, ensuring consistent quality for global pharmaceutical clients.

Sustainability Initiatives: Implementation of closed‑loop solvent recycling.

• ISO 9001 and GMP compliance
• Strategic alliances with multinational pharma companies
• Robust quality assurance and traceability systems

Download FREE Sample Report

Get Full Report

Outlook: The Future of the (R)-(-)-1-Methyl-3-hydroxypyrrolidine Market

As the pharmaceutical industry continues to prioritize high‑potency, enantiomerically pure APIs, the demand for chiral intermediates such as (R)-(-)-1‑Methyl‑3‑hydroxypyrrolidine is set to maintain a steady upward trajectory. The convergence of precision medicine, increasing investment in CNS‑focused therapeutics, and the shift toward greener manufacturing processes will shape the market landscape over the next decade.

Future Trends Shaping the Market

• Expansion of biocatalytic and enzyme‑based synthesis routes to reduce solvent usage and improve yield.
• Growth of contract manufacturing organizations offering end‑to‑end chiral synthesis services for emerging biotech firms.
• Increased regulatory focus on impurity profiling and chiral purity, driving demand for >99% ee products.
• Strategic partnerships between fine‑chemical suppliers and global pharma to accelerate pipeline development.
• Emergence of continuous flow technologies that lower production costs and enhance scalability.